CDK8 inhibition improves the efficacy of ER- and HER2-targeted drugs in breast cancer

被引：0
|
作者：
McDermott, M. S. [1 ]
Chumanevich, A. [1 ]
Liang, J. [1 ]
Chen, M. [1 ]
Altilia, S. [1 ]
Hennes, C. [1 ]
Roninson, I. B. [1 ]
Broude, E. V. [1 ]
机构：
[1] Univ South Carolina, Columbia, SC 29208 USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P3-07-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CDK8 inhibition potentiates anti-ER and anti-HER2 therapies in breast cancer
    McDermott, Martina S.
    Lim, Chang-uk
    Chen, Mengqian
    Chumanevich, Alexander
    Catroppo, James F.
    Gyorffy, Balazs
    Oliver, David
    Roninson, Igor B.
    Broude, Eugenia V.
    CANCER RESEARCH, 2015, 75
  • [2] Transcriptional antagonism by CDK8 inhibition improves therapeutic efficacy of MEK inhibitors
    Malone, Clare F.
    Kim, Minjee
    Alexe, Gabriela
    Forman, Alexandra B.
    Robichaud, Amanda
    Conway, Amy Saur
    Goodale, Amy
    Hatcher, John M.
    Gray, Nathanael S.
    Piccioni, Federica
    Stegmaier, Kimberly
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
    Malone, Clare F.
    Kim, Minjee
    Alexe, Gabriela
    Engel, Kathleen
    Forman, Alexandra B.
    Robichaud, Amanda
    Conway, Amy Saur
    Goodale, Amy
    Meyer, Ashleigh
    Khalid, Delan
    Thayakumar, Allen
    Hatcher, John M.
    Gray, Nathanael S.
    Piccioni, Federica
    Stegmaier, Kimberly
    CANCER RESEARCH, 2023, 83 (02) : 285 - 300
  • [4] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [5] Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+breast cancer
    Turnbull, A. K.
    Webber, V.
    McStay, D.
    Arthur, L.
    Martinez-Perez, C.
    Fernando, A.
    Renshaw, L.
    Keys, J.
    Clarke, R.
    Sims, A. H.
    Dixon, J. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
    Harris, C. A.
    Ward, R. L.
    Dobbins, T. A.
    Drew, A. K.
    Pearson, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1308 - 1317
  • [7] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
  • [8] HER2-targeted therapies beyond breast cancer - an update
    Yoon, Jeesun
    Oh, Do-Youn
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (09) : 675 - 700
  • [9] Cardiac Complications of HER2-Targeted Therapies in Breast Cancer
    Addetia K.
    DeCara J.M.
    Current Treatment Options in Cardiovascular Medicine, 2016, 18 (6)
  • [10] HER2-targeted therapies — a role beyond breast cancer
    Do-Youn Oh
    Yung-Jue Bang
    Nature Reviews Clinical Oncology, 2020, 17 : 33 - 48
12345